Phase 1/2 Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers
This study is testing two medications used together, neratinib and sodium valproate, to see how well they work against advanced solid tumors. Researchers want to find the safest dose and see if this combination can help patients with specific genetic mutations, such as RAS mutations.
You might be able to join if you have certain advanced solid tumors, including colon or pancreatic cancer with a RAS gene mutation. However, you cannot join if you have untreated brain tumors, severe ongoing diarrhea, or if you have taken neratinib before.
Participants will take the study medications in pill form to test safety and effectiveness against their cancer. Your health team will closely monitor you throughout the study to check for any side effects.
The study takes place in Richmond, Virginia, in the United States. Please note that this study is currently suspended, meaning it is not actively enrolling new participants at this moment.
- 1Tests a combination of two medications for advanced solid tumors
- 2Focuses especially on cancers with RAS gene mutations
- 3Currently suspended and not actively enrolling participants
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.